Ro

Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% year-over-year from $360M in 2023.

This reacceleration was driven overwhelmingly by the launch and scale-up of Ro Body, the company’s GLP-1–centered obesity management business, which became Ro’s primary growth engine by late 2023.

Historically, Ro’s revenue was dominated by Roman, its erectile dysfunction and men’s health franchise, which accounted for ~60% of revenue in 2021. As competition intensified and generic pricing compressed margins in ED, Roman’s relative contribution declined even as it remained a large, stable cash generator. By EoY 2024, we estimate ED/sexual health represented roughly ⅓ of total revenue.

In contrast, GLP-1 obesity management scaled from a negligible share (~3%) of revenue in 2021 to ~40% by EoY 2024, contributing the majority of incremental growth. Consumer credit card data shows total Ro sales roughly 2x’ing between January 2023 and August 2024, while GLP-1–related sales grew ~3x over the same period. We estimate Ro generated ~$370M in GLP-1 revenue in 2024, supported by a combination of monthly care subscriptions (~$145), pharmacy economics, and high average order values relative to legacy categories.

Ro’s remaining ~25% of revenue comes from a diversified set of non-obesity, non-ED lines — including dermatology, hair loss, fertility, and at-home diagnostics — which monetize the same vertically integrated telehealth, lab, and pharmacy infrastructure at lower ARPU but higher stability. These categories provide a recurring revenue base that both smooths volatility in GLP-1 pricing and serves as cross-sell surface area for the millions of users entering through Ro Body.

Ro’s most recent priced primary round was in February 2022, when it raised $150M in a round led by ShawSpring and participated in by existing backers including General Catalyst, FirstMark, and TQ. That round valued Ro at a $7B valuation, up from $5B in March 2021, and brought total funding to $1.0B in primary capital.

Ro started life in 2017 as Roman, with a focused insight about how telehealth adoption actually begins. The most receptive users are not people casually experimenting with virtual care, but patients dealing with high-intent, high-stigma conditions where discretion, speed, and convenience matter as much as clinical quality.

Erectile dysfunction, hair loss, herpes, and similar categories created a wedge where a direct-to-consumer experience felt strictly better than traditional care rather than a second-best substitute.

That initial wedge allowed Ro to reframe the doctor–patient interaction itself. Instead of patients searching for a doctor, waiting for an appointment, and compressing their concerns into a short in-office visit, Ro inverted the flow.

Patients begin with a structured online intake, clinicians review asynchronously, and care is delivered through a combination of messaging, phone, and video when necessary. Follow-ups are unlimited and ongoing, which makes the relationship feel continuous rather than transactional.

Over time, Ro's product has shifted away from being defined by the telehealth visit and toward being defined by the care pathway.

The real unit of value is not a single consultation, but a repeatable clinical loop that includes intake, eligibility checks, prescribing, fulfillment, monitoring, and renewal. This approach works especially well for medication-driven, protocol-heavy conditions where outcomes improve with consistent follow-up rather than episodic care.

That logic culminated in the formalization of ro.OS, which packages what Ro had been building internally into a unified operating layer across patients, providers, pharmacy, and labs.

The ambition is to make longitudinal care operationally cheap and reliable enough to scale, particularly for conditions that require ongoing medication management and testing rather than one-off diagnoses. In this framing, video visits are incidental. The product is the system that keeps care moving without friction across months or years.

In April 2025, Ro launched a direct integration with Novo Nordisk's NovoCare Pharmacy to offer branded Wegovy at a flat $499 per month for all dose strengths, billed as a "first-of-its-kind integration" that allows patients to consult and order manufacturer-sourced Wegovy without leaving the Ro app. This marked a shift from exclusively compounded semaglutide to a dual-track obesity offering that includes both brand-name and compounded GLP-1s, with fulfillment handled through CenterWell Pharmacy for the Wegovy channel.

Ro's most direct competitors are other D2C telehealth companies that pair performance marketing with condition-specific care pathways. Companies like Hims & Hers, Thirty Madison, and LifeMD follow a similar playbook: start with a narrow, high-intent category and expand horizontally into adjacent conditions.

In this segment, differentiation based purely on convenience or price is fragile. Generic medications are undifferentiated, marketing costs rise quickly, and patients can switch providers with minimal friction.

Ro's competitive defense is not meaningfully better telehealth, but deeper workflow integration that supports more complex, longer-duration care journeys involving labs, follow-ups, and insurance navigation.

The GLP-1 telehealth landscape has largely commoditized at the branded drug level. Novo Nordisk formalized partnerships with Ro, Hims & Hers, and LifeMD to distribute branded Wegovy at a uniform $499 per month cash price, effectively standardizing access to manufacturer-sourced supply across the three largest D2C telehealth players. This neutralized differentiation based on drug sourcing alone and shifted competition back to care experience, operational efficiency, and patient retention.

Large telehealth platforms such as Teladoc and Amwell operate primarily through employers, health plans, and health systems.

Historically, Ro avoided direct overlap by focusing on direct-pay patients, but that separation is eroding as Ro expands into chronic conditions where reimbursement, documentation, and outcomes tracking matter.

These incumbents benefit from distribution scale and embedded relationships, while Ro benefits from consumer brand strength and faster iteration.

The competitive question is whether Ro can maintain D2C velocity while building the operational rigor required to sell into payer and employer environments without losing its product simplicity.

An increasingly important competitive force comes from retail healthcare and pharmacy-adjacent models that can bundle basic telehealth into broader consumer ecosystems.

As pharmacy chains, retailers, and manufacturers themselves expand access channels, telehealth risks becoming a commodity feature.

Ro's response has been to integrate directly into manufacturer-supported distribution programs rather than competing against them.

By positioning itself as the experience and care orchestration layer on top of these channels, Ro aims to retain ownership of the patient relationship even as the underlying supply landscape shifts. The Wegovy integration exemplifies this strategy: Ro becomes the front-end care interface while Novo Nordisk and CenterWell Pharmacy handle sourcing and fulfillment, allowing Ro to offer branded drugs without taking on inventory or regulatory complexity associated with manufacturing partnerships.

Ro has begun positioning itself as data and distribution infrastructure for pharmaceutical manufacturers developing next-generation therapies. The company signed a research collaboration with Amgen to study barriers to GLP-1 access using de-identified patient data from Ro's platform, examining real-world hurdles like insurance coverage and prior authorization requirements.

The partnership positions Ro as a potential distribution partner for Amgen's MariTide, a long-acting obesity and diabetes candidate designed for monthly or less frequent dosing. This represents a strategic shift toward becoming infrastructure for next-generation GLP-1 launches, potentially giving Ro preferential access to emerging therapies before competitors while manufacturers use Ro's direct-to-patient data to understand payer dynamics and coverage gaps.

Ro's entry into other parts of the healthcare stack through acquiring new products to become vertically integrated is the key to their future growth.

As the largest player in D2C telemedicine, Ro's brand allows it to attract patients at lower CAC anywhere in the stack and then cross sell and upsell other services, allowing them to grow LTV beyond just selling generics.

Obesity represents Ro's most meaningful TAM expansion because it changes both the size of the market and the nature of the buyer.

Treating obesity as a chronic disease pulls Ro into ongoing care, higher per-patient revenue, and greater interaction with insurers. This expands the addressable market far beyond convenience-driven telehealth and into core healthcare spend.

If Ro can demonstrate durable outcomes and operational efficiency in obesity care, the category becomes a template for expanding into other chronic conditions where medication, monitoring, and adherence drive long-term value.

Ro's acquisitions in diagnostics, fertility testing, and in-home care delivery point toward a broader strategy of pulling more of the healthcare stack into the home.

These assets are not standalone growth bets so much as infrastructure that enables more complex care pathways without relying on external providers.

Owning diagnostics and sample collection allows Ro to close the loop between prescribing and monitoring, which is essential for scaling longitudinal care. Over time, this infrastructure can be reused across multiple conditions, increasing leverage as Ro adds new programs.

Longer term, Ro has the option to expand into employer and payer partnerships by positioning itself as the front door for specific conditions rather than a generalist telehealth provider.

This would allow Ro to access larger, more stable budgets, but it requires defensible outcomes data, deeper integrations, and a fundamentally different go-to-market motion.

ro.OS is the technical foundation for this expansion, but success depends on whether Ro can translate internal platform strength into externally credible value for payers and employers.

Ro's de-identified patient data and direct-to-patient platform are becoming infrastructure for pharmaceutical development and commercialization. The company has begun research collaborations with pharmaceutical manufacturers like Amgen to study real-world barriers to GLP-1 access—insurance coverage decisions, prior authorization requirements, payer criteria—to inform development of next-generation obesity therapies like MariTide.

This opens a path for Ro to monetize its platform as observational research infrastructure and preferential distribution channel for next-generation therapies, expanding beyond selling existing drugs into shaping how new ones are developed and brought to market.

Bundling commoditization: Condition-focused D2C telehealth is increasingly easy to replicate, and bundling alone may not be enough to sustain differentiation. The April 2025 Novo Nordisk partnerships with Ro, Hims & Hers, and LifeMD offering identical Wegovy pricing at $499 per month illustrate how quickly competitive moats erode when manufacturers standardize access across telehealth channels. If patients view Ro's offerings as interchangeable with cheaper alternatives, retention and lifetime value will suffer as acquisition costs rise.

GLP-1 supply and regulatory volatility: Ro's weight loss growth is exposed to drug availability, insurer coverage decisions, and regulatory changes around compounding. The shift from compounded semaglutide to branded Wegovy integration in April 2025 partially de-risks compounding restrictions, but introduces new dependencies on manufacturer pricing, allocation decisions, and promotional economics. Sudden shifts in access, reimbursement, or Novo's channel strategy could materially impact demand and unit economics.

Late-stage valuation pressure: Ro's past valuation levels set high expectations for growth and eventual liquidity. If growth slows or margins compress, the gap between operational performance and valuation assumptions could constrain strategic flexibility and talent retention.